Header graphic for print
LimeGreenIP News

Category Archives: Patents

Subscribe to Patents RSS Feed

Every bit counts: Could Blockchain be a solution for e-mobility?

Does blockchain technology open up new avenues in the field of electromobility? Can decentralized processes that are controlled by a large network be used to convert individual mobility on the road to electrified vehicles and sustainable energy resources? These questions are the starting point of the following blog post of our series on blockchain. In addition

Hogan Lovells Comes to Taiwan To Help Financial Supervisory Commission

Partner Ted Mlynar, senior consultant Amelia Lin, Dr. Zheng-yi Shon, Dean of the School of Management of Tainan University of Technology, and representatives from Microsoft and Acer in Taiwan, visited Wellington Koo, Chairman of the Financial Supervisory Commission (FSC) and his staff to discuss accelerating the pace of development of Taiwan’s financial technology. Dr. Shon noted

Brexit Bill – Impact on patents

The UK government’s draft EU Withdrawal Bill (the “Brexit Bill“) aims to incorporate EU directives and regulations into UK domestic law in their current form immediately following Brexit (“Retained EU Law“).  This article considers the impact the Brexit Bill will have on some key patent issues. The Brexit Bill and EU Decisions In addition to

Interview: Emerging issues in the connected cars and autonomous vehicles market are influencing SEPs and IP transactions

In this hoganlovells.com interview, partner Celine Crowson addresses the relationship between standard-essential patents (SEPs) and the connectivity technologies used in connected and autonomous vehicles (AVs). She discusses the increased exposure of automotive manufacturers and suppliers to litigation from patent aggressors, how new autonomous vehicle technologies influence intellectual property transactions, and challenges involved in setting telecom-related

Dutch Supreme Court hands down landmark decision on infringement of second medical use patents

On 3 November 2017, the Dutch Supreme Court (Hoge Raad) handed down a landmark decision on the infringement of second medical use patents in the Merck Sharp & Dohme Corp. (“MSD”) v. Teva Pharma B.V. and Pharmachemie B.V. (“Teva”) case relating to MSD’s Swiss type second medical use patent protecting a combination therapy of ribavirin

IPunkt – German language (Deutsch) IP newsletter

Our German network is delighted to provide IP news and updates in German language. Please click the link below to read the latest IPunkt edition. IPunkt – Deutsch (German language) German language IP news is also regularly published on our cross-practice DE blog

Blockchain links into the pharma supply chain

In November’s issue of Pharma Times Magazine, Mark Marfé explores the current applications of Distributed Ledger Technologies (DLT), such as blockchain, and how DLT can be used and developed to benefit companies in the pharma industry. This article looks at DLT’s role in overcoming particular challenges facing the pharma supply chain, including anti-counterfeiting, product recall, information sharing, access to financing as well as the development of smart contracts. Read

UPC and Germany: Status update – Constitutional complaint, ratification timeline and more

Background The constitutional complaint against the UPC ratification that was lodged with the Federal Constitutional Court in Germany earlier this year has received a lot of attention over the past few months as it could have the potential to considerably delay the entry into force of the Agreement on a Unified Patent Court (UPCA). Pursuant

Europe: Blockchain – Practical and legal challenges

The increasing digitization of the private as well as economic realm is undeniable. The European Commission is constantly pushing the Digital Single Market forward. In the same breath as the ubiquitous phenomenon of digitalization, blockchain technology is all too often mentioned. A bright future is predicted for it even if the actual applications have, admittedly, been rare in practice so far.

Webinar – 26 September: Blockchain and IP, Navigating Emerging Issues

On Tuesday, September 26, Partner Ted Mlynar will speak on a webinar panel covering blockchain technology, smart contracts, and more. The webinar, “Blockchain and IP: Navigating Emerging Issues,” will familiarize counsel with some of the current and potential uses of blockchains, and more broadly, distributed ledger technology (DTL). The panel will also discuss the legal and

Wearable-tech turns luxury as designer brands collaborate with tech firms

In August’s issue of Jewellery Focus, Mark Marfé, a senior lawyer in our IPMT practice in London, was interviewed on the rise of wearable technology. The wearable market has seen an increase in “luxury” products as well as an expansion from wrist pieces to voice recorder necklaces, fitness tracker brooches and even rings that monitor

“The Connected World”: Intellectual Value Event – London

Please join us on 17 October when we will be hosting our annual Intellectual Value seminar – this year focusing on ‘The Connected World’ and a variety of topics from across the Internet of Things. From factories to offices, vehicles to homes, smart technologies are transforming every aspect of our society – and they’re here to stay. Businesses need

U.S. – What does the Impression Products v. Lexmark decision mean for drug companies? 5 takeaways

Last May, the U.S. Supreme Court issued a highly-anticipated decision in Impression Products, Inc. v. Lexmark Int’l, Inc., reversing the Federal Circuit and holding that, when a patent holder sells a product, it exhausts all of its patent rights in the product, regardless of certain restrictions that the patent holder sought to impose on further resale.

IP Newsletter – French language / Français

Our Paris team is delighted to provide IP news and updates in French language. The latest edition, #16 from September 2017 can be accessed at the link below. Lettre d’actualité IPMT – Français (French language)

IP is at the heart of life sciences innovation

In recent years, technology and innovation has advanced at an unprecedented pace. Flying taxi drones, self-driving cars and 3D-printers immediately come to mind. However, exciting progress has been made in life sciences and the healthcare sector as well. With CRISPR, bionic limbs and 3D-printed tissue, the medical sector has never been closer to eliminating disease

US: Bioprinting – A life sciences and legal innovation

The patent eligibility of bioprinted products and processes has not been squarely addressed by the legislature or tested in courts. Arlene Chow and Nitya Anand explain what could be done in the future in this article, first published in issue #35 of IPPro Patents. The medical industry is undergoing a radical transformation, thanks to recent

Major IP reforms foreshadowed in China’s Pharma sector.

On 12 May 2017, the Chinese Food and Drug Administration (the “CFDA”) issued several draft policies aimed at overhauling of the current regulations governing the Chinese pharma and medical device sector (the “Draft Policies”). Amongst the Draft Policies, those outlined in Circular No.55 would, if implemented, establish a more robust patent linkage system, a more

U.S. Patent Legislation: The STRONGER Patents Act of 2017

In June, three democratic senators (Chris Coons from Delaware, Dick Durbin from Illinois, and Mazie Hirono from Hawaii) and one republican senator (Tom Cotton from Arkansas) introduced the “STRONGER Patents Act of 2017.” One of the motivations for the bill appears to be that the U.S. Chamber of Commerce recently ranked the U.S. patent system

US: Update on pleading standards in patent cases

It has been nearly two years since the Federal Rules of Civil Procedure were amended to eliminate Form 18, the World War II-era sample form that authorized plaintiffs to commence patent infringement litigation with only bare-bones allegations. In the absence of Form 18, it is widely accepted that patent infringement complaints are now governed by

UK Supreme Court hands down landmark ruling in favour of Eli Lilly

Following last Friday’s (7 July 2017) unusual move of advance publication of the outcome of the case, the UK Supreme Court now published the reasons for its decision in the long-running Actavis v Eli Lilly case. The reasons show that the UKSC found for Lilly under every point being considered. The result is that Actavis’ products

Italian time-machine : Limitation of the duration of an SPC may be decided by the Italian Patent Office

The Board of Appeal of the Italian Patent Office (Commissione dei Ricorsi), by decision published on June 26, 2017, acknowledged the right of the patent holder to ask the Italian Patent Office for the limitation of the duration of a supplementary protection certificate (SPC) further to its recalculation on account of an earlier marketing authorisation. Background

Hogan Lovells Successfully Acts for Eli Lilly in UK Supreme Court Patent Ruling

In an unusual move, the UK Supreme Court (UKSC) has given its key conclusions in the long running Actavis v Eli Lilly case ahead of giving the full judgment. The UKSC allowed Eli Lilly’s appeal and held that Actavis’ products directly infringe Lilly’s patent in the United Kingdom, France, Italy and Spain. The full judgment